{"ticker": {"uuid": "54cfd307-351b-427d-833b-a2dfbb08b665", "symbol": "ACRV", "name": "Acrivon Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics trades below cash value despite promising cancer therapy data and upcoming clinical milestones.", "summary": "Acrivon Therapeutics (ACRV) is trading below its cash value despite promising early clinical data from its AP3 platform, which includes a 50% response rate in serous endometrial cancer with drug ACR-368. Upcoming catalysts are Phase 2b data for ACR-368 and Phase 1 expansion resul", "url": "https://pluang.com/en/news-feed/acrivon-therapeutics-dipandang-gagal-dibangun-untuk-presisi", "source_name": "Pluang", "published_at": "2026-07-13T13:41:24", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 78, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNM0lYcE0wSVpDX1hhZndUbUlJMnV4TUsxYXU4SWh5WVlGa3VaZmtfa1owU2k3S3p1TFZyTUVNY1pIN1h0WVNieGJzSTc0T09rMVNuS1ZCWUR5bi1ib050MTYtN0g4cnVrTUJubzlzMl9IVmJ6VVhPb1V3QzMyMXJMTGNFV1BsLXpsSW1vNHExRHNQeTJwbUZQcUR1YXVQQzJRU3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T08:44:48+00:00", "published_display": "13 Jul 2026 08:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T13:30:58+00:00", "published_display": "11 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV) as of July 2, 2026. It includes key financial metrics such as market cap, income, sales, EPS, various ratios, stock performance, and insider/institutional ownership. The data is presented to of", "url": "https://finviz.com/stock?t=ACRV&p=d&b=1&ty=oc", "source_name": "Finviz", "published_at": "2026-07-03T10:10:35", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Earnings", "summary": "This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV), including its last closing price, market capitalization, enterprise value, income, and sales figures. It also lists various financial ratios, EPS estimates, insider and institutional ownership", "url": "https://finviz.com/stock?t=ACRV&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-02T06:10:13", "published_display": "02 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. \u2013 NASDAQ:ACRV", "summary": "This article provides financial information for Acrivon Therapeutics, Inc. (NASDAQ: ACRV), specifically focusing on its enterprise value to EBITDA forward. It indicates that this data is part of a larger financial overview available on TradingView, which includes market data, new", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:47", "published_display": "29 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Acrivon Therapeutics, Inc. \u2013 NASDAQ:ACRV", "summary": "This article displays the \"Price to sales forward\" financial metric for Acrivon Therapeutics, Inc. (NASDAQ: ACRV) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:39", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV)", "summary": "This article provides an overview of Acrivon Therapeutics, Inc. (NASDAQ: ACRV) stock, including its current price, market capitalization, and analyst estimates. It also covers financial actuals and estimates, stock performance, and key dates such as the next earnings report. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:49", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52", "summary": "Entities affiliated with RA Capital, linked to director Dr. Derek DiRocco, have been granted 20,275 stock options in Acrivon Therapeutics (ACRV) at an exercise price of $1.52 per share, expiring in 2036. This is a routine, compensation-related grant, not an open-market trade, des", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-0b3095835782.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:41:24", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52", "summary": "Acrivon Therapeutics director Michael John Tomsicek was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. These compensation-related options will vest on the day before the company's next annual meeting, contingent on his continuou", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-5f64f20da1a3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T18:10:49", "published_display": "23 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds", "summary": "Acrivon Therapeutics director Derek DiRocco was granted a stock option for 20,275 shares of common stock at an exercise price of $1.52, expiring on June 16, 2036. This option is held for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with DiRocco disclaiming", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-9e5a2797422b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T17:39:41", "published_display": "23 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options", "summary": "Acrivon Therapeutics director Sharon Shacham was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest on the date immediately preceding Acrivon's next annual meeting of stockholders, provided Shacham continues he", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-17ba6b16e052.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:42:00", "published_display": "22 Jun 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Acrivon Therapeutics Inc. related to June 22. The article provides the company's stock symbol (ACRV) and a general market update, but no specific details from the Form 4 filing are included in the content.", "url": "https://za.investing.com/news/stock-market-news/form-4-acrivon-therapeutics-inc-for-22-june-93CH-4338486", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T20:10:12", "published_display": "22 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike", "summary": "Acrivon Therapeutics (ACRV) director Palani Santhosh received a grant of 20,275 stock options with an exercise price of $1.52 per share and an expiration date of June 16, 2036. The options will vest on the date immediately preceding the company's next annual meeting of stockholde", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-b39bd440a278.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52", "summary": "Acrivon Therapeutics director Charles M. Baum received a grant of 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest immediately before the company's next annual stockholder meeting, contingent on his continuous servic", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-91e769408860.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director granted options on 20,275 shares", "summary": "Acrivon Therapeutics director Ivana Magovcevic-Liebisch was granted options to acquire 20,275 shares of the company's common stock at an exercise price of $1.52 per share. This grant is a compensation-related award, not an open-market purchase, and the options will vest on the da", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-4f3c8870ceda.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Shareholders Approve Expanded Equity Plan and Directors", "summary": "Acrivon Therapeutics, Inc. shareholders approved an expanded equity incentive plan, increasing the share pool to 8,606,723 shares, and elected Michael Tomsicek and Charles Baum as Class I directors. This decision, with a 73.21% quorum, signals strong shareholder support for the c", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ACRV/pressreleases/2547214/acrivon-shareholders-approve-expanded-equity-plan-and-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T04:09:15", "published_display": "19 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics shareholders approve equity plan changes and director elections", "summary": "Acrivon Therapeutics shareholders have approved amendments to the company's 2022 Equity Incentive Plan, increasing the shares available for equity awards by 3,000,000 to a total of 8,606,723. Additionally, Michael Tomsicek and Charles Baum were elected as Class I directors, and P", "url": "https://ng.investing.com/news/sec-filings/acrivon-therapeutics-shareholders-approve-equity-plan-changes-and-director-elections-93CH-2564086", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T16:10:47", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors", "summary": "Acrivon Therapeutics, Inc. (ACRV) shareholders approved an Amended and Restated 2022 Equity Incentive Plan, expanding the number of shares authorized for equity awards to 8,606,723, including an additional 3,000,000 shares. The plan also features an annual automatic share reserve", "url": "https://www.stocktitan.net/sec-filings/ACRV/8-k-acrivon-therapeutics-inc-reports-material-event-bd5c7efc0a0f.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:40:07", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon amends equity plan, shareholders approve 3,000,000-share increase", "summary": "Acrivon Therapeutics, Inc. (ACRV) has approved an amended and restated 2022 Equity Incentive Plan. This includes a 3,000,000-share increase to the reserve and an automatic annual share-reserve adjustment through 2032. The plan aims to secure and retain services, provide incentive", "url": "https://www.tradingview.com/news/tradingview:4fdd87b954492:0-acrivon-amends-equity-plan-shareholders-approve-3-000-000-share-increase/", "source_name": "TradingView", "published_at": "2026-06-17T21:40:07", "published_display": "17 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Inc (ACRV) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Acrivon Therapeutics Inc (ACRV) as of a recent update. It lists key institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The data indicates the level of institutio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:07", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gabelli Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8", "summary": "Gabelli has initiated coverage on Acrivon Therapeutics (ACRV.US) with a Buy rating. The firm has set a target price of $8 for the company's stock.", "url": "https://www.moomoo.com/news/post/71539581/gabelli-initiates-acrivon-therapeutics-acrvus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-16T15:10:36", "published_display": "16 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8", "summary": "Oppenheimer has initiated coverage on Acrivon Therapeutics (ACRV.US) with a 'Buy' rating. The firm has set a target price of $8 for the company's stock.", "url": "https://www.moomoo.com/news/post/71543422/oppenheimer-initiates-acrivon-therapeutics-acrvus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-15T21:40:41", "published_display": "15 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Acrivon Therapeutics Inc (ACRV) stock, including its latest trading price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's financial health, insider transactions, and upcom", "url": "https://finviz.com/stock?t=ACRV", "source_name": "Finviz", "published_at": "2026-06-08T11:39:13", "published_display": "08 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Acrivon Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant, comprising options to purchase 111,150 shares of common stock, was made on May 15, 2026, with an exercise price based on the closing price that day. The options w", "url": "https://finance.yahoo.com/sectors/healthcare/articles/acrivon-therapeutics-announces-inducement-grant-200000942.html", "source_name": "Market source", "published_at": "2026-06-06T10:40:03", "published_display": "06 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics\u2019 SWOT analysis: stock shows promise in cancer pipeline", "summary": "Acrivon Therapeutics, a clinical-stage biopharmaceutical company, is advancing a pipeline of precision oncology candidates for difficult-to-treat cancers, with its lead program, ACR-368, showing an improved objective response rate of 52% in serous endometrial cancer. The company ", "url": "https://www.investing.com/news/swot-analysis/acrivon-therapeutics-swot-analysis-stock-shows-promise-in-cancer-pipeline-93CH-4704500", "source_name": "Investing.com", "published_at": "2026-05-22T16:09:59", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics to Present at TD Cowen\u2019s 7th Annual Oncology Innovation Summit", "summary": "Acrivon Therapeutics announced its President and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen\u2019s 7th Annual Oncology Innovation Summit on May 26, 2026. The company is a clinical-stage oncology firm developing precision medicines gui", "url": "https://www.globenewswire.com/news-release/2026/05/21/3299221/0/en/Acrivon-Therapeutics-to-Present-at-TD-Cowen-s-7th-Annual-Oncology-Innovation-Summit.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T03:39:03", "published_display": "22 May 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon CEO to join TD Cowen cancer innovation webcast May 26", "summary": "Acrivon Therapeutics (Nasdaq: ACRV) CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen\u2019s 7th Annual Oncology Innovation Summit on May 26, 2026, at 9:00 a.m. ET. The company, a clinical-stage biotechnology firm, will discuss its precision", "url": "https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-ldm7ac7ljyb9.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:41:26", "published_display": "21 May 2026 11:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants", "summary": "Acrivon Therapeutics, Inc. (ACRV) reported equity awards to senior leaders, including President and CEO Peter Blume-Jensen and EVP Kristina Masson, in the form of Restricted Stock Units (RSUs) and common stock grants. The awards include 72,706 RSUs and 180,095 shares of Common St", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-e89a2b8e2f83.html", "source_name": "Stock Titan", "published_at": "2026-05-21T03:09:30", "published_display": "21 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPXzc1RVM0NnhUdi0wRVgwT1k1dGJqRHJ1OTJUY3BiclplYUhyTGJPbDk5YkV3WW5vWXBCVHY5RG1GSExQdnRFQnBQaDl5QjZibmlhS2lMOGZLOUZ5UTRvQTF0V0hKR3dFV2o5QmlncmZINHhMX29rU05rRlluNmtJUkhQZk5FRFFvTHBJUUNjUFFMbUtLOXlQOU9aWkFsV2xTUVNIcXNHZTlRcWd6QVM1MmV0T3YzemlRTlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSk13N0tSdmtSZ0pYRWEzWnpVVDhIUFRydGQ4Q2VUNnA2QnpMSy1xOVJ6dklid1RCNGFhdXo3dmtKT2Y1SDBkbkxaaWlkRERQaE0tdm9jOFhNdDNBUGtMU2w4QTF2eFVWQmlZUEQ0b0VGeGtZOXdRal9OX0pPaUNJT2diTWJzVlp5VU1vNUQ1WGNhdW00TkJuamIwSVlET0wwa3Zvamx1cW1fLVZJbFlRRnRsNVNLRWYxazlDOWpnWWZNc2hMREttSWcweFA1b0lNRno3OQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Acrivon Therapeutics Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/news/acrivon-therapeutics-q1-loss-narrows-211421163.html", "source_name": "MT Newswires", "published_at": "2026-05-13T21:14:21+00:00", "published_display": "13 May 2026 21:14", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxNTzRnU2NCLVltZjlyWGY0TXRKLW9tbjg0alJNMFVpcEE2cHVsc3lkeXh0MzJJSmVRRllQSEUzN2NkWVUxOHc3cENNc1NzSUZZcVEyY0w1MHNORVlxVUFlMWQ2YktnQWYxdWFELTk1QjhsNllGaVF6YWZubXVZMW01R1RfeDNHN2M5LWdDeC1TeVdGbnNSNVB4U2I0MXV1RDBBMmJlYUc4WXp5RXdWY2VHTG9aZU1ERW01MFVTa1o3WTRhUXp4T09XRjRPVWdTRWphdVdmaXlZT2R6cGtnc2tETENzZnY3dzNjY0JobWFCM0dINk5MNDAyLWRwenY2MmVtdmg4QUg5b1dRQ0dTdUpzc0d3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$ACRV stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNSGVFZVVRS2UwcW14T0RXaU5BU3FwbUd1TGZkMXhaUVFKdnA3dDVlZDlSVC1pa09Nek9kWTRMZXNqX25SZEZrYlh1aWtFZ0oxVUU3ZTFjM1pPUm9zR2hiRVRSMFV5aFREVkgxa1VmSFZTU0JQVzY3RHBlVmwxbDVIcm02UlZOa09TcHNNaVVNU1NlQkxfV2tjek5uYi15c0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPWWItT19uQWVkbl9sZkcxVnRqMV9fN3ZRSi1qRXNGM09pWjBtMEhYTG84UWpCSC1JRGtpaTlMZGgyLTJDY1B3aUtPaHE5aEFGblhoazNoU2JfUUJYRzExVkxJNmRKUHRNZ2JwRG9MblVkMWNKNlROQlhTcDZaSHdxZWJlMlFGODF2emszcw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ACRV stock is down 16% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYmswTkRzUDdmaGdlQVhuZW41WVhZdjhIM2ZoYW02aWtwaFhyaThVcmxHSEJkWG5EM0g5S2tnTXJ0SzJMWkQ1NnNwb3U5SEdtYVNPOTFDS0k3SGZxb1BpdktKNVRFeTNjT1p0QWdJdGF3UUdVQ3pIQkV4Qk8zdGQ5ZGNJeklLVEVYUFgzX0xCQ19hMjI2b2c1bUhQUXBla1hnYTRj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release | ACRV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPc1B1NndOR05iUGtKRkdYX0FURWpRSkxxSEpFa3NBZnhmQWhMMV93S2NTRkpMLXBSRUR2UGNFWlRmS1RLaUhialhqbXRCRmN5ME9nd3ZxNFo2OG9LdEhzaWFNc2xta1F2RGpOalQ0MXFCRTRqbFNxYzJ1ejZIbmlhWVJ1TnpUcGVaMmFZbS0wOWVZNEpib3hkTF9sQUpwTHp6RXhwMmFHMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics trades below cash value despite promising cancer therapy data and upcoming clinical milestones.", "summary": "Acrivon Therapeutics (ACRV) is trading below its cash value despite promising early clinical data from its AP3 platform, which includes a 50% response rate in serous endometrial cancer with drug ACR-368. Upcoming catalysts are Phase 2b data for ACR-368 and Phase 1 expansion resul", "url": "https://pluang.com/en/news-feed/acrivon-therapeutics-dipandang-gagal-dibangun-untuk-presisi", "source_name": "Pluang", "published_at": "2026-07-13T13:41:24", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 78, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNM0lYcE0wSVpDX1hhZndUbUlJMnV4TUsxYXU4SWh5WVlGa3VaZmtfa1owU2k3S3p1TFZyTUVNY1pIN1h0WVNieGJzSTc0T09rMVNuS1ZCWUR5bi1ib050MTYtN0g4cnVrTUJubzlzMl9IVmJ6VVhPb1V3QzMyMXJMTGNFV1BsLXpsSW1vNHExRHNQeTJwbUZQcUR1YXVQQzJRU3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T08:44:48+00:00", "published_display": "13 Jul 2026 08:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T13:30:58+00:00", "published_display": "11 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV) as of July 2, 2026. It includes key financial metrics such as market cap, income, sales, EPS, various ratios, stock performance, and insider/institutional ownership. The data is presented to of", "url": "https://finviz.com/stock?t=ACRV&p=d&b=1&ty=oc", "source_name": "Finviz", "published_at": "2026-07-03T10:10:35", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Earnings", "summary": "This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV), including its last closing price, market capitalization, enterprise value, income, and sales figures. It also lists various financial ratios, EPS estimates, insider and institutional ownership", "url": "https://finviz.com/stock?t=ACRV&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-02T06:10:13", "published_display": "02 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. \u2013 NASDAQ:ACRV", "summary": "This article provides financial information for Acrivon Therapeutics, Inc. (NASDAQ: ACRV), specifically focusing on its enterprise value to EBITDA forward. It indicates that this data is part of a larger financial overview available on TradingView, which includes market data, new", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:47", "published_display": "29 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Acrivon Therapeutics, Inc. \u2013 NASDAQ:ACRV", "summary": "This article displays the \"Price to sales forward\" financial metric for Acrivon Therapeutics, Inc. (NASDAQ: ACRV) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:39", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV)", "summary": "This article provides an overview of Acrivon Therapeutics, Inc. (NASDAQ: ACRV) stock, including its current price, market capitalization, and analyst estimates. It also covers financial actuals and estimates, stock performance, and key dates such as the next earnings report. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:49", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52", "summary": "Entities affiliated with RA Capital, linked to director Dr. Derek DiRocco, have been granted 20,275 stock options in Acrivon Therapeutics (ACRV) at an exercise price of $1.52 per share, expiring in 2036. This is a routine, compensation-related grant, not an open-market trade, des", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-0b3095835782.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:41:24", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52", "summary": "Acrivon Therapeutics director Michael John Tomsicek was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. These compensation-related options will vest on the day before the company's next annual meeting, contingent on his continuou", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-5f64f20da1a3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T18:10:49", "published_display": "23 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds", "summary": "Acrivon Therapeutics director Derek DiRocco was granted a stock option for 20,275 shares of common stock at an exercise price of $1.52, expiring on June 16, 2036. This option is held for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with DiRocco disclaiming", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-9e5a2797422b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T17:39:41", "published_display": "23 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options", "summary": "Acrivon Therapeutics director Sharon Shacham was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest on the date immediately preceding Acrivon's next annual meeting of stockholders, provided Shacham continues he", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-17ba6b16e052.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:42:00", "published_display": "22 Jun 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Acrivon Therapeutics Inc. related to June 22. The article provides the company's stock symbol (ACRV) and a general market update, but no specific details from the Form 4 filing are included in the content.", "url": "https://za.investing.com/news/stock-market-news/form-4-acrivon-therapeutics-inc-for-22-june-93CH-4338486", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T20:10:12", "published_display": "22 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike", "summary": "Acrivon Therapeutics (ACRV) director Palani Santhosh received a grant of 20,275 stock options with an exercise price of $1.52 per share and an expiration date of June 16, 2036. The options will vest on the date immediately preceding the company's next annual meeting of stockholde", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-b39bd440a278.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52", "summary": "Acrivon Therapeutics director Charles M. Baum received a grant of 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest immediately before the company's next annual stockholder meeting, contingent on his continuous servic", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-91e769408860.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) director granted options on 20,275 shares", "summary": "Acrivon Therapeutics director Ivana Magovcevic-Liebisch was granted options to acquire 20,275 shares of the company's common stock at an exercise price of $1.52 per share. This grant is a compensation-related award, not an open-market purchase, and the options will vest on the da", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-4f3c8870ceda.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:42:00", "published_display": "22 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Shareholders Approve Expanded Equity Plan and Directors", "summary": "Acrivon Therapeutics, Inc. shareholders approved an expanded equity incentive plan, increasing the share pool to 8,606,723 shares, and elected Michael Tomsicek and Charles Baum as Class I directors. This decision, with a 73.21% quorum, signals strong shareholder support for the c", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ACRV/pressreleases/2547214/acrivon-shareholders-approve-expanded-equity-plan-and-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T04:09:15", "published_display": "19 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics shareholders approve equity plan changes and director elections", "summary": "Acrivon Therapeutics shareholders have approved amendments to the company's 2022 Equity Incentive Plan, increasing the shares available for equity awards by 3,000,000 to a total of 8,606,723. Additionally, Michael Tomsicek and Charles Baum were elected as Class I directors, and P", "url": "https://ng.investing.com/news/sec-filings/acrivon-therapeutics-shareholders-approve-equity-plan-changes-and-director-elections-93CH-2564086", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T16:10:47", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors", "summary": "Acrivon Therapeutics, Inc. (ACRV) shareholders approved an Amended and Restated 2022 Equity Incentive Plan, expanding the number of shares authorized for equity awards to 8,606,723, including an additional 3,000,000 shares. The plan also features an annual automatic share reserve", "url": "https://www.stocktitan.net/sec-filings/ACRV/8-k-acrivon-therapeutics-inc-reports-material-event-bd5c7efc0a0f.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:40:07", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon amends equity plan, shareholders approve 3,000,000-share increase", "summary": "Acrivon Therapeutics, Inc. (ACRV) has approved an amended and restated 2022 Equity Incentive Plan. This includes a 3,000,000-share increase to the reserve and an automatic annual share-reserve adjustment through 2032. The plan aims to secure and retain services, provide incentive", "url": "https://www.tradingview.com/news/tradingview:4fdd87b954492:0-acrivon-amends-equity-plan-shareholders-approve-3-000-000-share-increase/", "source_name": "TradingView", "published_at": "2026-06-17T21:40:07", "published_display": "17 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Inc (ACRV) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Acrivon Therapeutics Inc (ACRV) as of a recent update. It lists key institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The data indicates the level of institutio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:07", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gabelli Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8", "summary": "Gabelli has initiated coverage on Acrivon Therapeutics (ACRV.US) with a Buy rating. The firm has set a target price of $8 for the company's stock.", "url": "https://www.moomoo.com/news/post/71539581/gabelli-initiates-acrivon-therapeutics-acrvus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-16T15:10:36", "published_display": "16 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8", "summary": "Oppenheimer has initiated coverage on Acrivon Therapeutics (ACRV.US) with a 'Buy' rating. The firm has set a target price of $8 for the company's stock.", "url": "https://www.moomoo.com/news/post/71543422/oppenheimer-initiates-acrivon-therapeutics-acrvus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-15T21:40:41", "published_display": "15 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRV - Acrivon Therapeutics Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Acrivon Therapeutics Inc (ACRV) stock, including its latest trading price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's financial health, insider transactions, and upcom", "url": "https://finviz.com/stock?t=ACRV", "source_name": "Finviz", "published_at": "2026-06-08T11:39:13", "published_display": "08 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Acrivon Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant, comprising options to purchase 111,150 shares of common stock, was made on May 15, 2026, with an exercise price based on the closing price that day. The options w", "url": "https://finance.yahoo.com/sectors/healthcare/articles/acrivon-therapeutics-announces-inducement-grant-200000942.html", "source_name": "Market source", "published_at": "2026-06-06T10:40:03", "published_display": "06 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics\u2019 SWOT analysis: stock shows promise in cancer pipeline", "summary": "Acrivon Therapeutics, a clinical-stage biopharmaceutical company, is advancing a pipeline of precision oncology candidates for difficult-to-treat cancers, with its lead program, ACR-368, showing an improved objective response rate of 52% in serous endometrial cancer. The company ", "url": "https://www.investing.com/news/swot-analysis/acrivon-therapeutics-swot-analysis-stock-shows-promise-in-cancer-pipeline-93CH-4704500", "source_name": "Investing.com", "published_at": "2026-05-22T16:09:59", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics to Present at TD Cowen\u2019s 7th Annual Oncology Innovation Summit", "summary": "Acrivon Therapeutics announced its President and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen\u2019s 7th Annual Oncology Innovation Summit on May 26, 2026. The company is a clinical-stage oncology firm developing precision medicines gui", "url": "https://www.globenewswire.com/news-release/2026/05/21/3299221/0/en/Acrivon-Therapeutics-to-Present-at-TD-Cowen-s-7th-Annual-Oncology-Innovation-Summit.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T03:39:03", "published_display": "22 May 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon CEO to join TD Cowen cancer innovation webcast May 26", "summary": "Acrivon Therapeutics (Nasdaq: ACRV) CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen\u2019s 7th Annual Oncology Innovation Summit on May 26, 2026, at 9:00 a.m. ET. The company, a clinical-stage biotechnology firm, will discuss its precision", "url": "https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-ldm7ac7ljyb9.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:41:26", "published_display": "21 May 2026 11:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants", "summary": "Acrivon Therapeutics, Inc. (ACRV) reported equity awards to senior leaders, including President and CEO Peter Blume-Jensen and EVP Kristina Masson, in the form of Restricted Stock Units (RSUs) and common stock grants. The awards include 72,706 RSUs and 180,095 shares of Common St", "url": "https://www.stocktitan.net/sec-filings/ACRV/form-4-acrivon-therapeutics-inc-insider-trading-activity-e89a2b8e2f83.html", "source_name": "Stock Titan", "published_at": "2026-05-21T03:09:30", "published_display": "21 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPXzc1RVM0NnhUdi0wRVgwT1k1dGJqRHJ1OTJUY3BiclplYUhyTGJPbDk5YkV3WW5vWXBCVHY5RG1GSExQdnRFQnBQaDl5QjZibmlhS2lMOGZLOUZ5UTRvQTF0V0hKR3dFV2o5QmlncmZINHhMX29rU05rRlluNmtJUkhQZk5FRFFvTHBJUUNjUFFMbUtLOXlQOU9aWkFsV2xTUVNIcXNHZTlRcWd6QVM1MmV0T3YzemlRTlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSk13N0tSdmtSZ0pYRWEzWnpVVDhIUFRydGQ4Q2VUNnA2QnpMSy1xOVJ6dklid1RCNGFhdXo3dmtKT2Y1SDBkbkxaaWlkRERQaE0tdm9jOFhNdDNBUGtMU2w4QTF2eFVWQmlZUEQ0b0VGeGtZOXdRal9OX0pPaUNJT2diTWJzVlp5VU1vNUQ1WGNhdW00TkJuamIwSVlET0wwa3Zvamx1cW1fLVZJbFlRRnRsNVNLRWYxazlDOWpnWWZNc2hMREttSWcweFA1b0lNRno3OQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/news/acrivon-therapeutics-q1-loss-narrows-211421163.html", "source_name": "MT Newswires", "published_at": "2026-05-13T21:14:21+00:00", "published_display": "13 May 2026 21:14", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxNTzRnU2NCLVltZjlyWGY0TXRKLW9tbjg0alJNMFVpcEE2cHVsc3lkeXh0MzJJSmVRRllQSEUzN2NkWVUxOHc3cENNc1NzSUZZcVEyY0w1MHNORVlxVUFlMWQ2YktnQWYxdWFELTk1QjhsNllGaVF6YWZubXVZMW01R1RfeDNHN2M5LWdDeC1TeVdGbnNSNVB4U2I0MXV1RDBBMmJlYUc4WXp5RXdWY2VHTG9aZU1ERW01MFVTa1o3WTRhUXp4T09XRjRPVWdTRWphdVdmaXlZT2R6cGtnc2tETENzZnY3dzNjY0JobWFCM0dINk5MNDAyLWRwenY2MmVtdmg4QUg5b1dRQ0dTdUpzc0d3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ACRV stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNSGVFZVVRS2UwcW14T0RXaU5BU3FwbUd1TGZkMXhaUVFKdnA3dDVlZDlSVC1pa09Nek9kWTRMZXNqX25SZEZrYlh1aWtFZ0oxVUU3ZTFjM1pPUm9zR2hiRVRSMFV5aFREVkgxa1VmSFZTU0JQVzY3RHBlVmwxbDVIcm02UlZOa09TcHNNaVVNU1NlQkxfV2tjek5uYi15c0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPWWItT19uQWVkbl9sZkcxVnRqMV9fN3ZRSi1qRXNGM09pWjBtMEhYTG84UWpCSC1JRGtpaTlMZGgyLTJDY1B3aUtPaHE5aEFGblhoazNoU2JfUUJYRzExVkxJNmRKUHRNZ2JwRG9MblVkMWNKNlROQlhTcDZaSHdxZWJlMlFGODF2emszcw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ACRV stock is down 16% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYmswTkRzUDdmaGdlQVhuZW41WVhZdjhIM2ZoYW02aWtwaFhyaThVcmxHSEJkWG5EM0g5S2tnTXJ0SzJMWkQ1NnNwb3U5SEdtYVNPOTFDS0k3SGZxb1BpdktKNVRFeTNjT1p0QWdJdGF3UUdVQ3pIQkV4Qk8zdGQ5ZGNJeklLVEVYUFgzX0xCQ19hMjI2b2c1bUhQUXBla1hnYTRj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release | ACRV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPc1B1NndOR05iUGtKRkdYX0FURWpRSkxxSEpFa3NBZnhmQWhMMV93S2NTRkpMLXBSRUR2UGNFWlRmS1RLaUhialhqbXRCRmN5ME9nd3ZxNFo2OG9LdEhzaWFNc2xta1F2RGpOalQ0MXFCRTRqbFNxYzJ1ejZIbmlhWVJ1TnpUcGVaMmFZbS0wOWVZNEpib3hkTF9sQUpwTHp6RXhwMmFHMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 61, "sentiment_summary": {"positive": 19, "negative": 3, "neutral": 39, "score": 56, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 19.75, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 10.95, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 19, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.96, "latest_week": "2026-07-10", "one_week_move": 14.0, "four_week_move": 32.4, "twelve_week_move": 10.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.325923, "market_dynamics_buy_signal": false, "relative_strength": -4.614766, "fair_value_gap": -58.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.9885, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+14.0% over one week, +32.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "Quiver Quantitative", "count": 4}, {"label": "Finviz", "count": 3}, {"label": "Barron's", "count": 3}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+14.0% over one week, +32.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?"}], "updated_at": "2026-07-17T22:21:24.289905+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}